Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Analysts coverage

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Jun 15, 2021 8:08pm

192 Views

Post# 33393330

RE:RE:RE:Analysts coverage

You are welcome, maybe for now it's not a bad idea to hide that section under a rock! As per website I like it,same material but organized so NASH/oncology investors get the picture as under each section they can see which studies/researches lead to why and how these protocols came together. The menu might looks crowded but the reason is they are involved with many projects from commercial to preclinical and various trial stages( phase 3 NASH included). It's a good website and good start.

palinc2000 wrote:
Thx
its under stock info
Does not have s tab all by itself .... for now!!!

scarlet1967 wrote:

https://www.theratech.com/investors/stock-information/analyst-coverage

palinc2000 wrote: The analysts tab is missing from the website......???